BRAF and astrocytoma (excluding glioblastoma): In pediatric patients with central nervous system (CNS) neoplasms, such as ependymoma, medulloblastoma and infiltrating astrocytoma, WES detected clinically pertinent Tier 1 (BRAF V600E, NTRK alterations, and C19MC amplification) and Tier 2 variants (BRAF fusion transcripts) [76].